A New Drug Application, NDA for short, is the formal application for marketing authorization of a medicinal product in the United States. It is submitted to the Food and Drug Administration and bundles the information on which the authority assesses safety, efficacy, quality, and product information. The NDA is a US application type and not a designation for a European or Japanese procedure.<\/p>\n
An NDA consolidates the results of medicinal product development in a regulatory dossier. This includes information on the composition, manufacture, and control of the product, non-clinical investigations, clinical data, statistical analyses, safety information, and the proposed labeling. Which documents are required to what extent depends on the product, development pathway, and legal requirements. 21 CFR Part 314 contains the FDA regulations on applications for marketing a new drug.<\/p>\n
The application does not merely serve for the filing of study reports. The FDA reviews whether the submitted evidence supports the requested application, whether the manufacturing and control information is adequate, and whether the benefit-risk assessment supports an approval. After submission, the authority can ask questions or request additional information. A complete and consistent presentation of data origin, analyses, and safety profile is therefore essential for the evaluability of the dossier.<\/p>\n
Section 505 of the Federal Food, Drug, and Cosmetic Act distinguishes several pathways. An NDA under 505(b)(1) contains full reports of investigations of safety and effectiveness. An NDA under 505(b)(2) is also an NDA, but a portion of the information required for approval may rely on studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The FDA cites, among other things, published literature or previous agency findings for a listed drug in this context.<\/p>\n
An Abbreviated New Drug Application, ANDA, must be differentiated from this. It is the legal pathway for generics under Section 505(j) and is not based on an independent full evidence program like a 505(b)(1) NDA. The choice between ANDA and 505(b)(2) requires a product-specific legal and scientific review. A Biologics License Application, BLA, is in turn the license application for biological products under Section 351 of the Public Health Service Act and 21 CFR Part 601. BLA and NDA are therefore not synonymous dossier designations.<\/p>\n
The US NDA is submitted to the FDA under US law. The Japan \u2013 New Drug Application, on the other hand, concerns a marketing authorization application for Japan, the review of which is accompanied by the Pharmaceuticals and Medical Devices Agency, PMDA, and the approval of which takes place in the Japanese system. Both procedures can use a Common Technical Document and ICH principles, but are not the same regulatory submission.<\/p>\n
For a Japanese submission, the expectations of the PMDA, its consultation mechanisms, and the applicability of foreign data must be considered. In particular, strategies on ethnic factors and bridging according to ICH E5 or the planning of multiregional clinical trials according to ICH E17 can become relevant. An FDA interaction, a US study program, or a US NDA does not replace this Japanese assessment. Conversely, a Japan \u2013 New Drug Application is not an NDA within the meaning of Section 505 of the US Act.<\/p>\n
The NDA strategy influences study planning and data standards long before the actual submission. Endpoints, control group, statistical planning, analysis populations, and safety follow-up must support the proposed indication. The connection between clinical data, CMC documents, and the intended product information must also be traceable. WHODrug Global can be used for the standardized coding of medications in clinical data, but is not a marketing authorization application and does not replace regulatory data assessment.<\/p>\n
Full-service CROs such as Mediconomics support the submission strategy, the project management of clinical trials, monitoring, data management, biostatistics, pharmacovigilance, and medical writing. They help in particular to consistently prepare clinical study reports, tables, listings, and safety narratives, and to organize the handovers between development, quality, and regulatory affairs in such a way that an NDA dossier can be traceably compiled.<\/p>\n
Is every NDA a 505(b)(1) NDA?<\/strong><\/p>\n No. A 505(b)(2) NDA is also an NDA, but relies in part on information from studies without its own right of reference.<\/p>\n Is an ANDA an abbreviated NDA?<\/strong><\/p>\n The ANDA is a distinct legal pathway for generics under Section 505(j). It must be differentiated from an NDA under 505(b)(1) or 505(b)(2).<\/p>\n Is a BLA the NDA for biologics?<\/strong><\/p>\n No. The BLA is a license application for biological products under the Public Health Service Act; distinct legal bases and regulations apply to it.<\/p>\n A New Drug Application, NDA for short, is the formal application for marketing authorization of a medicinal product in the United States. It is submitted to the Food and Drug Administration and bundles the information on which the authority assesses safety, efficacy, quality, and product information. The NDA is a US application type and not […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6703","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6703\/revisions"}],"predecessor-version":[{"id":7437,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6703\/revisions\/7437"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6703"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n